Arena Pharmaceuticals, Inc (NASDAQ:ARNA) headed up to close at $5.46 on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Arena Pharmaceuticals, Inc (NASDAQ:ARNA) rose by 6.83%. The shares opened at a price of $5.41, which touched the intraday high of $5.61 and headed to a close of $5.46. Around 9.67 million exchanged hands over the trading day and an average volume of 5.69 million shares were traded over a 30 day period. The 52-week low of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) shares is $4.05 and its 52-week high is $11.00. The company has a market capitalization of $1.19 billion.                                        

About the company

Arena Pharmaceuticals, Inc (NASDAQ:ARNA) was incorporated on 14 April 1997. It is a bio-pharmaceutical company that concentrates on discovering & development as well as commercialization of drugs that target the G protein-coupled-receptors. The company’s 100%-owned subsidiary is named Arena Pharmaceuticals GmbH. It  has granted Eisai commercialization rights for BELVIQ in the U.S. Arena Pharmaceuticals, Inc (NASDAQ:ARNA)’s other oral drug-candidates are APD811- this particular drug is an agonist of a prostacyclin-receptor that is intended for treating pulmonary arterial-hypertension- this is currently in a Phase 1 clinical-trial.

Another one of the company’s drug candidates is temanogrel. This is an inverse-agonist of serotonin 2A-receptor and is intended for use in the treatment of thrombotic-diseases. This drug has completed its single & multiple-ascending dose-Phase I trials; The next drug candidate is APD334- this is an agonist of the S1P1-receptor that is intended for treatment of autoimmune-diseases, & APD371- this is an agonist of the cannabinoid-receptor-2 that is intended for treating pain.

This is in preclinical development. In 2012 June, the U.S FDA approved Arena Pharmaceuticals, Inc (NASDAQ:ARNA)’s internally-discovered drug, BELVIQ. This drug is used for chronic weight-management in the adults who are overweight and have comorbidity or are obese. Arena Pharmaceuticals, Inc (NASDAQ:ARNA)’s R&D programs also include GPR119 & earlier-stage programs. These span numerous therapeutic areas. The 3 trials included in the company’s BELVIQ Phase-III development-program are BLOOM & BLOSSOM as well as BLOOM-DM.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.